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ABSTRACT
ObjectivesToexaminesurvivalandlongtermcessationof
injecting in a cohort of drug users and to assess the
influence of opiate substitution treatment on these
outcomes.
Design Prospective open cohort study.
Setting A single primary care facility in Edinburgh.
Participants 794 patients with a history of injecting drug
use presentingbetween 1980 and 2007; 655 (82%) were
followedupbyintervieworlinkagetoprimarycarerecords
and mortality register, or both, and contributed 10390
person years at risk; 557 (85%) had received opiate
substitution treatment.
MainoutcomemeasuresDurationofinjecting:yearsfrom
first injection to long term cessation, defined as last
injection before period of five years of non-injecting;
mortality before cessation; overall survival.
Results In the entire cohort 277 participants achieved
long term cessation of injecting, and 228 died. Half of the
survivors had poor health related quality of life. Median
duration from first injection to death was 24 years for
participants with HIV and 41 years for those without HIV.
For each additional year of opiate substitution treatment
the hazard of death before long term cessation fell 13%
(95%confidenceinterval17%to9%)afteradjustmentfor
HIV, sex, calendar period, age at first injection, and
history of prison and overdose. Conversely exposure to
opiatesubstitutiontreatment was inverselyrelatedto the
chances of achieving long term cessation.
Conclusions Opiate substitution treatment in injecting
drug users in primary care reduces this risk of mortality,
with survival benefits increasing with cumulative
exposure to treatment. Treatment does not reduce the
overall duration of injecting.
INTRODUCTION
Injection drug use is an important public health pro-
blem with a prevalence of around 1-2% among young
adultsintheUnitedKingdomandastandardisedmor-
tality ratio over 10 times that of the general
population.
1 Deaths in those who inject opiates are
mainly a consequence of overdose and bloodborne
infection.
2 The principal treatment for dependent
users is opiate substitution therapy, commonly oral
methadone,
3 which in the UK is mostly delivered in
primary care settings. Opiate substitution treatment
can reduce opiate use, mortality, and transmission of
bloodborne infections, though most evidence comes
from relatively short term studies.
4-8
Short periods of cessation from injecting are rela-
tively common,
9 but few studies have long enough fol-
low-up to observe long term cessation, and the impact
ofopiatesubstitutiontreatmentontheoverallduration
of injecting is unclear.
10
We report on a follow-up study of the Edinburgh
addiction cohort.
11 This study included injecting drug
users, most of whom were using heroin, recruited
through Muirhouse Medical Group, a single primary
care facility in a deprived area of Edinburgh, during a
rapid local HIV epidemic.
12 We describe the duration
of injecting and survival and assess the influence of
opiate substitution treatment and other factors on
these outcomes.
METHODS
Data source
Methods are described in detail elsewhere.
1113 Briefly,
between 1980 and 2006 all patients at a large primary
care facility in Edinburgh who reported a history of
injecting drug use were recruited to the study. Opiate
substitution treatment was publicly funded and acces-
sible to patients throughout the study period, in keep-
ing with national guidelines. Cohort members were
flagged with the General Register Office for Scotland
to allow for tracing of deaths and changes of general
practitioner. From October 2005 to November 2007
we attempted to contact all surviving cohort members
toconductafollow-upinterview.Informationwasalso
collected from primary care notes when these were
available.
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571 were still alive at the start of follow-up and 432
(75%) were interviewed. By the end of follow-up, five
of those we interviewed had died, bringing the total
numberofdeathsto228(29%).Wewereabletofollow
up655(82%)usingprimarycarerecords,includingfor
187 (82%) of those who died. One hundred and thirty
nine (18%) participants were lost to follow-up.
11
Instruments
We used a coding sheet to systematically extract data
on clinical history from primary care records. The
causes of death were transcribed from the death certi-
ficates provided by national mortality registers and
grouped into the underlying cause of death from
HIV, external injury, liver disease, and other causes.
We developed a life grid
14 questionnaire administered
by an interviewer to collect retrospective self reported
dataoninjectingdruguseoveralifetime
11andassessed
currenthealthstatusbasedonthealcoholusedisorders
identification test (AUDIT),
15 the hospital anxiety and
depression scale (HADS),
16 and a self rated visual ana-
logue scale of current health state (EQ-VAS).
17
Primary outcomes
Time to event variables were duration in years from
first injection to death (from primary care records) or
the start of a period of long term cessation of injecting
(from follow-up interviews).
11 We defined long term
cessation as at least five consecutive years without
injecting before the last follow-up or death as this was
consistent with other cohorts where the probability of
relapse was relatively low after five years.
18-20 In our
study, for the 377 interviewees with a history of cessa-
tion of injecting, 111 relapsed after their last cessation
ofatleastthreemonths,and97(87%)didsowithinfive
years (range 0.25-23.25 years).
Exposure variables
The main exposure variable was receipt of opiate sub-
stitutiontreatment(suchasoralmethadone,buprenor-
phine, dihydrocodeine)
21 ascertained from primary
care records. Data were available on cumulative
months and years of exposure from year of injection
to the outcome (long term cessation or death). Opiate
substitutiontreatmentintheperioddefininglongterm
cessation(fiveyearsafterlastinjection)wasincludedin
the exposure variable, with treatment after this period
excluded.
Asdeadparticipantswereincludedinbothanalyses,
in addition to opiate substitution treatment we consid-
ered the following covariates extracted from primary
care notes: sex, age at first injection, calendar year at
first injection (<1986, 1986), HIV status (negative,
positive), periods in prison (none, once, more than
once);and clinicalhistory(no,yes) ofoverdoserequir-
ing treatment at an accident and emergency depart-
ment, problem drinking, referrals for serious mental
health issues, and self harm.
Analysis procedures
We used discrete time survival models for the analysis
ofthetimefromstartinginjectingtodeathorlongterm
cessationbecausetheinformationonthetimesofonset
and cessation events was available only in whole
years.
2223 Firstly, overall survival was analysed with a
logistic model. Secondly, time to death before long
term cessation and time to long term cessation were
analysed with a competing risk model.
24 The compet-
ingriskapproachwasrequiredbecausetheoccurrence
of the death event prevents an individual from experi-
encing long term cessation and vice versa. Moreover,
this framework enabled the assessment of the poten-
tially different role of covariates on the probability of
occurrence of the two competing events, allowing a
better understanding of each cause of outcome. We
used a multinomial logistic hazard model to model
the log odds of death before long term cessation and
long term cessation simultaneously.
2526 Individuals
contribute one year of exposure from when they start
injecting to the time they experience one of the events
or are censored at interview.
We used dummy variables representing years from
first injection to estimate (non-parametrically) time
varying hazards, in both the logistic and multinomial
logistic models. We used a complete case analysis
approach as we had insufficient information on non-
responders to impute missing data. We excluded the
41 surviving participants with less than six years’ fol-
low-up since their first injection from the competing
risk analysis because they had insufficient follow-up
to measure long term cessation. The best fitting multi-
nomial logistic model included duration variables of
1 year, 2-10 years, 11-15 years, and 16-38 years from
initiation of injecting and the opiate substitution treat-
ment and age at onset of injecting variables as contin-
uous variables. We fitted and found evidence for an
interaction between opiate substitution treatment and
duration, suggesting that the effect of treatment dif-
fered over time (likelihood ratio test χ
2=36.19, df=6,
P<0.0001). As none of the individual interactions
between opiate substitution treatment and duration
were significant for survival (r=−0.15 (SE 0.27),
P=0.57, for 2-10 years’ duration; r=−0.07 (SE 0.26),
Table 1 |Characteristics at recruitment and follow-up in 794
participants in Edinburgh addiction cohort. Figures are
numbers (percentages), unless stated otherwise
Characteristic Data
Male 543 (68)
Calendar period of recruitment:
1980-9 361 (46)
1990-9 201 (25)
2000-7 231 (29)
Mean (SD) age at first injection (years) 19.9 (5.1)
Mean (SD) age at recruitment (years) 26.7 (6.3)
Mean (SD, range) years of follow-up 10.2 (6.8, <1-25)
Interviewed at follow-up 432 (54)
Lost to follow-up 139 (18)
Dead at study end point 228 (29)
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P=0.18,for16-38years’duration),welimitedtheinter-
action to long term cessation only. All analyses were
conductedwithStatastatisticalsoftware(version10.1).
RESULTS
Table 1 shows characteristics of the cohort at recruit-
ment. Table 2 shows follow-up outcomes and current
drug use and health status of interviewees.
Among interviewees, 302 (70%) were currently
receiving opiate substitution treatment, primarily
methadone; 135 (31%) were currently injecting, of
whom 112 (83%) were also receiving opiate substitu-
tion treatment; and 165 (38%) had achieved long term
cessation,ofwhom106(64%)werecurrentlyreceiving
opiate substitution treatment. Most interviewees were
current smokers (403, 93%). For other measures, 20%
(87) were problem drinkers, 48% (209) were anxious,
26% (114) were depressed, and 52% (226) had poor
health related quality of life. Interviewees who
achieved long term cessation had lower levels of mor-
bidity.
Among the 654 with data extracted from primary
care case notes, 558 (85%) had a history of opiate sub-
stitutiontreatment:79%(439)hadreceivedmethadone,
73%(410)dihydrocodeine,7%(37)buprenorphine,and
1% (8) other opiates; 314 patients had had multiple
forms ofopiatesubstitutiontreatment. Ahistory ofper-
iods in prison was recorded in primary care notes for
360(55%);281(43%)hadahistoryofproblemdrinking
and 237 (36%) had a history of overdose requiring hos-
pital treatment; 199 (30%) had been referred to specia-
list mental health services; and 196 (30%) had a history
of self harm. In total, 189 (29%) participants were HIV
antibody positive.
By the study end point, 228 (29%) participants had
died (table 3). The leading causes of death were HIV
(102,45%),drugoverdose(55,24%),andliverdisease/
injury (37, 16%). More than three quarters of deaths
from drug overdose were among those who did not
achieve long term cessation (78%), and drug overdose
deaths accounted for 38% (43) of all deaths in that
group. Most deaths could be attributed to injecting
drug use (table 3), with many of the remaining deaths
due to associated problems with other substance use,
particularly tobacco and alcohol, or comorbid mental
illness.
Overall survival and competing risks: survival and long
term cessation
Figure 1 shows survival by HIV status. Median survi-
val for HIV positive patients was 24 years compared
with41yearsforHIVnegativepatients(forpatientsset
to median exposure to opiate substitution treatment,
median age at first injection, onset <1986, no prison
history, and no history of overdose).
Among those whodied and intervieweeswhose first
injection had been at least six years before follow-up
(n=566), 49% (277) achieved long term cessation, 16%
(91) died before achieving long term cessation, and
35% (198) survived but had not achieved long term
cessation by follow-up. Of those who died before
achieving long term cessation, within 25 years after
their first injection, half of HIV positive participants
had died compared with 10% (9) of HIV negative par-
ticipants. Opiate substitution treatment was associated
with increased survival (that is, decreased time to
death). Table 4 shows that for each year of opiate sub-
stitution treatment, the probability of death was
reducedby10%.Withoutadjustmentforotherfactors,
survivalwasalsoreducedinthosewithaprisonhistory
and history of overdose and was negatively associated
with age at onset of injecting (table 4). There was no
difference in survival by sex or history of alcohol pro-
blems, self harm, or serious mental illness. Evidence
for improved survival with opiate substitution treat-
ment remained after adjustment (for HIV, history of
Table 2 |Injecting and health status of interviewees in Edinburgh addiction cohort at follow-
up. Figures are numbers (percentages)
Characteristic
Total
(n=432)
Long term cessation of injecting*
Not achieved
(n=241)
Achieved
(n=165)
P valuefor difference
(χ2 test)
Current injecting drug users 135 (31) 135 (56) ——
Current opiate substitution
treatment
302 (70) 196 (81) 106 (64) <0.05
Smoker 403 (93) 229 (95) 149 (90) >0.05
Problem drinker† 87 (20) 55 (23) 25(15) >0.05
Anxious‡ 209 (48) 128 (53) 71(43) <0.05
Depressed§ 114 (26) 70 (29) 40 (24) >0.05
Low subjective QoL¶ 226 (52) 144 (60) 82 (50) >0.05
*Sample restricted to 406 participants with >5 years’ observation since their first injection.
†AUDIT score of ≥16, indicating high risk or harmful drinking in past year.
15
‡HADS anxiety subscale score ≥11, indicating caseness.
16
§HADS depression subscale score ≥11, indicating caseness.
16
¶EqVAS z score <−1.96 based on UK population norms by age, sex, and smoking status.
40
Table 3 |Primary cause of death in Edinburgh addiction
cohort. Figures are numbers (percentages) of participants
All deaths
(n=228)
Deathsbeforelongterm
cessation (n=112)
HIV 102 (45) 43 (38)
Injury:
Drug overdose* 55 (24) 43 (38)
Suicide† 15 (7) 8 (7)
Homicide 1 (<1) 0
Liver:
Liver disease 26 (11) 8 (7)
Alcohol related 11 (5) 2 (2)
Other causes:
Cardiovascular disease 7 (3) 4 (4)
Injecting related 2 (1) 2 (2)
Lung/throat cancer 2 (1) 1 (1)
Respiratory disease 2 (1) 0
Unascertained 2 (1) 1 (1)
Other 3 (1) 0
*Including 12 deaths from ingested substances after long term injecting
cessation.
†Six of 15 suicides were drug overdoses classified as intentional self
harm: paracetamol (n=3), insulin (n=1), nifedipine (n=1), dihydrocodeine
and alcohol (n=1).
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period of onset), with the hazard of death reduced by
13% (95% confidence interval 17% to 9%, P<0.001).
Figure2showsthatforpatientswhodonotstartopiate
substitution treatment (unexposed), a quarter will be
dead within 25 years of their first injection compared
with 6% of those with more than five cumulative years
ofexposuretoopiatesubstitutiontreatment(withother
factors set to HIV negative, median age at first injec-
tion,onset<1986,noprisonhistory,nohistoryofover-
dose). After adjustment for opiate substitution
treatment and other covariates (see above), the prob-
ability of death before long term cessation was
increasedalmostsixfold (3.5to10.1) forthose infected
with HIV and twofold (1.3 to 3.1) for those with a his-
toryofheroinoverdoseandthe effectofprisonhistory
on survival was diluted. The effect of calendar period
(onset of injecting from 1986) on survival switched
from insufficient or weak evidence of a protective
effect (hazard ratio 0.74, P=0.22) to evidence of a
more than twofold increase in the probability of
death before long term cessation (1.1 to 4.0, P=0.02)
after adjustment for HIV infection in particular and
other covariates (opiate substitution treatment, history
of overdose, age at first injection, prison history, sex).
Opiatesubstitutiontreatmentwasassociatedwithan
increased duration of injecting (that is, time to long
term cessation): for each year of treatment, before
adjustment, duration was increased by 11% (table 4).
Table 4 shows also that after adjustment for key cov-
ariates (sex, HIV infection, age at first injection, calen-
darperiodofonset,prisonhistory,historyofoverdose)
and an interaction between opiate substitution treat-
ment and time, the impact of opiate substitution treat-
mentondurationwanesover time—that is,decreasing
theprobabilityofcessationby0.73(0.65to0.81)inthe
first year and then, as the interactions are all greater
than 1, by 0.89 in years 2-10, 0.95 in years 11-15, and
0.91 in years 16-38. (The latter are generated by multi-
plying the interaction terms with the effect of opiate
substitutiontreatment.)Figure3showsthatforpatients
who did not start opiate substitution treatment, the
mediandurationofinjectingwasfiveyears(withnearly
30%ceasingwithin a year) comparedwith20 yearsfor
those with more than five years of exposure to
treatment(withotherfactorssettoHIVnegative,med-
ianageatfirstinjection,onset<1986,noprisonhistory,
no history of overdose). Figure 3 also shows that the
difference in the probability of long term cessation
between those who do and those who do not receive
opiate substitution treatment narrows over time.
Table 4 also shows that the probability of cessation,
after adjustment for opiate substitution treatment and
other covariates in the model, was lower for injecting
drug users with more than one period of prison
recorded (0.57, 0.42 to 0.78) and for those injecting
from 1986 (0.54, 0.38 to 0.77). There was weak evi-
dence that women had a 30% higher probability of
achieving long term cessation, but after adjustment
the difference was diluted (1.11, 0.84 to 1.47). Age at
onsetwasassociatedwitha6%(3%to9%)higherprob-
ability of cessation; and there was weak evidence that
HIV infection was also associated with a higher prob-
ability of cessation (1.32, 0.99 to 1.75).
Based on data available from the 369 interviewed
patients, those exposed to opiate substitution treat-
mentreportedinjectinglessfrequentlywhilereceiving
treatment compared with periods out of treatment
(mean 157 v 273 days a year, t=−3.9, df=171,
P<0.001).Forthosewhoachievedlongtermcessation,
however, the number of total days injecting tended to
be lower amongthose whowere not exposedtoopiate
substitution treatment compared with those who were
exposed (878 v 1469 days, t=−0.9, df=140, P=0.36).
DISCUSSION
This follow-up study of the Edinburgh addiction
cohort shows the chronic nature and multiple adverse
health consequences of injecting drug use.
27 In our
cohortofinjectorsrecruitedfromprimarycarearound
halfofthoseinfectedwithHIVwill diewithin24years
of starting injecting, and even for those without HIV
median survival was 41 years, suggesting half of those
who start injecting in late adolescence will be dead by
middle age. Quality of life and health status of surviv-
ing injecting drug users also was poor.
Our results confirm the beneficial effects of opiate
substitution treatment delivered in routine primary
careoverlongperiods.Wefoundadose-responserela-
tion between exposure to such treatment and survival
before long term cessation. The overall median dura-
tionofinjecting,however,waslongerforinjectingdrug
users who were exposed to opiate substitution treat-
ment. It is argued that this treatment confers its health
benefit through promoting injection cessation.
328Our
data did not support this hypothesis and suggest that it
conferred health benefits irrespective of whether
injecting drug users continued injecting, though users
injectedless oftenwhen receiving treatment,asconsis-
tently shown in clinical trials and observational
studies.
29 Nonetheless, the cumulative total number
of injections is probably greater in those exposed to
opiate substitution treatment (as a high proportion of
thosewhodidnotreceivesuchtreatmentstopinjecting
within the first year of onset). Opiate substitution
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bidity through improving social functioning, reducing
criminal activity, and maintaining regular contact
between individuals and primary care services.
30
HIV infection was concentrated among cohort par-
ticipants recruited in the early 1980s, and deaths
related to HIV peaked before the introduction of
more effective treatments.
13 HIV infection reduced
Table 4 |Competing risk (hazard) from year of first injection to achieving long term cessation or death before long term cessation in participants in
Edinburgh addiction cohort whose first injection had been at least six years before follow-up (multinomial logistic regression model)
Variable (No in
group)
Died before achieving long term cessation Long term cessation achieved before death/follow up
No (%)
Hazard ratio (95% CI)
No (%)
Hazard ratio (95% CI)
Unadjusted P value Adjusted* P value Unadjusted P value Adjusted* P value
Sex:
Male (387) 67 (17) 1.00 —— — 184 (48) 1.00 —— —
Female (179) 25 (14) 0.96 (0.60 to 1.52) 0.86 1.09 (0.67 to 1.79) 0.73 94 (52) 1.30 (1.01 to 1.68) 0.05 1.11 (0.84 to 1.47) 0.45
Age first injection (median=18, IQR=16-22):
Age — 1.00 —— — — 1.00 —— —
1 year later — 1.05 (1.01 to 1.10) 0.03 1.09 (1.04 to 1.15) <0.001 — 1.06 (1.04 to 1.09) 0.00 1.06 (1.03 to 1.09) 0.00
Year of first injection:
<1986 (351) 69 (20) 1.00 —— — 220 (63) 1.00 —— —
≥1986 (215) 23 (11) 0.74 (0.46 to 1.20) 0.22 2.13 (1.13 to 4.01) 0.02 57 (27) 0.58 (0.43 to 0.78) 0.00 0.54 (0.38 to 0.77) 0.00
Years of exposure to opiate substitution treatment (median=4.3, IQR=0-8.5):
None — 1.00 —— — — 1.00 —— —
For each year of
exposure
— 0.90 (0.87 to 0.94) <0.001 0.87 (0.83 to 0.91) <0.001 — 0.89 (0.86 to 0.91) <0.001 0.73 (0.65 to 0.81) <0.001
Prison exposure:
None (267) 27 (10) 1.00 —— — 152 (57) 1.00 —— —
≤1 year (109) 17 (16) 1.31 (0.71 to 2.42) 0.38 1.31 (0.70 to 2.46) 0.39 48 (44) 0.66 (0.47 to 0.92) 0.01 0.81 (0.57 to 1.14) 0.23
>1 year (190) 48 (25) 1.98 (1.23 to 3.19) 0.01 1.39 (0.84 to 2.32) 0.20 77 (41) 0.56 (0.43 to 0.75) <0.001 0.57 (0.42 to 0.78) <0.001
Clinical history of overdose:
No (352) 43 (12) 1.00 —— — 193 (55) 1.00 —— —
Yes (214) 49 (23) 1.68 (1.11 to 2.54) 0.01 2.00 (1.29 to 3.12) <0.001 84 (39) 0.64 (0.49 to 0.83) <0.001 0.82 (0.63 to 1.09) 0.17
HIV status:
No (384) 35 (9) 1.00 —— — 162 (42) 1.00 —— —
Yes(182) 57 (31) 3.81 (2.49 to 5.83) <0.001 5.97 (3.53 to
10.12)
<0.001 115 (63) 1.66 (1.30 to 2.12) <0.001 1.32 (0.99 to 1.75) 0.06
Clinical history of alcohol problems:
No (315) 43 (14) 1.00 —— — 158 (50) 1.00 —— —
Yes (251) 49 (20) 1.23 (0.81 to 1.86) 0.33 —— 119 (47) 0.81 (0.64 to 1.04) 0.10 ——
Clinical history of serious mental health:
No (389) 64 (16) 1.00 —— — 180 (46) 1.00 —— —
Yes (177) 28 (16) 1.00 (0.64 to 1.57) 0.99 —— 97 (55) 1.23 (0.96 to 1.59) 0.10 ——
Clinical history of self harm:
No (392) 63 (16) 1.00 —— — 197 (50) 1.00 —— —
Yes (174) 29 (17) 1.12 (0.72 to 1.75) 0.61 —— 80 (46) 0.99 (0.76 to 1.29) 0.94 ——
Years to event (from first injection to death or long term cessation):
<1-1 (67) 1 (1) —— 0.0001 (0.00001
to 0.001)
<0.001 66 (99) —— 0.1 (0.07 to 0.3) <0.001
2-10 (222) 33 (15) —— 0.0005 (0.0002 to
0.002)
<0.001 122 (55) —— 0.03 (0.01 to 0.05) <0.001
11-15 (115) 24 (21) —— 0.002 (0.0006 to
0.007)
<0.001 51 (44) —— 0.03 (0.02 to 0.07) <0.001
16-38 (110) 34 (31) —— 0.005 (0.002 to
0.01)
<0.001 38 (35) —— 0.03 (0.02 to 0.07) <0.001
Constrained interaction between years from first injection to long term cessation and opiate substitution treatment exposure:
<1-1 ——— ————— 1.0 —
2-10 ——— ————— 1.2 (1.1 to 1.4) <0.001
11-15 ——— ————— 1.3 (1.2 to 1.5) <0.001
16-38 ——— ————— 1.3 (1.1 to 1.4) <0.001
IQR=interquartile range.
*Adjusted for sex, age first injection, year first injection, exposure to opiate substitution treatment, prison history, overdose, HIV status, and interaction for hazard of long term cessation
between duration of injecting and exposure to opiate substitution treatment.
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increase in hazard of death before long term cessation.
The risk of acquiring HIV infection associated with
injecting in Scotland became widely known in 1986.
12
Afteradjustment,ouranalysessuggestthatparticipants
who started injecting before 1986, and were perhaps
more likely to have HIV positive contemporaries,
had a shorter duration of injecting.
3132
One long term cohort study found that episodes in
prison seem to promote cessation of injection.
33 We
foundnoevidenceforthisinourdata;onthecontrary,
more than one prison episode almost doubled the
overall hazard of death and decreased the probability
of achieving long term cessation.
Strengths and limitations
The strengths of our study were its size, community
base, and long duration of follow-up and the detailed
information over time available from interview and
administrative sources.
We lost 139 participants (18% of the whole cohort
and 25% of survivors), a favourable follow-up rate
compared with many other cohorts of injecting drug
users.
34 Follow-up was poorer in those who had
moved, in some cases because local general practi-
tioners or directors of public health were unwilling to
providecontactdetails.
11 Thosewhomwe failedtofol-
low-up might have differed from the others and thus
introduce bias. Unfortunately we were unable to con-
duct any imputation for missing data to test for bias
because of a lack of information. Our participants
might not be representative of all injecting drug users.
Importantly, the cohort might over-represent depen-
dent injecting drug users and under-represent those
who inject for only a short time because recruitment
occurred several years after onset and was based on
users presenting to primary care and reporting their
injecting drug use. In a sensitivity analysis, exclusion
of participants who had injected for less than a year
(who are less likely to be dependent or have a fatal
overdose and more likely to stop injecting before
dying than those who inject for over a year) had no
effect on the hazard ratios reported in table 3. Overall
survival and time to long term cessation in the popula-
tion, however, might be underestimated and
overestimated, respectively, if short term injectors
were substantially under-represented.
35 Equally, the
cohort was at the epicentre of the national HIV epi-
demic,differingfromotherUKbasedcohortsofinject-
ingdrugusers
3637butcomparablewithsomeEuropean
cohorts.
132
Theuseofprimarycarerecordsasourprincipaldata
source, on exposure and covariates and cessation out-
comesinthosewhodied,limitedadjustmentforpoten-
tialconfounders.Injectingdruguserswhodonotenter
opiate substitution treatment might have different
characteristics (for example, be less chaotic or depen-
dent) that explain their higher cessation rate and con-
found the relation between long term cessation and
opiate substitution treatment. If that is true, we would
also expect to see a lower risk of death among those
who did not receive opiate substitution treatment,
whichisthereverseofwhatweobserved.Itisnotinevi-
table that any factor, such as exposure to opiate substi-
tution treatment, that reduces risk of death in injecting
drug users will also increase overall duration of inject-
ing. For example, prison history increased both mor-
tality and injecting duration.
Information on injection cessation from interviews
or patients’ notes, or both, might have been biased.
Forexamplerecipientsofopiatesubstitutiontreatment
might be more likely to have their injection status dis-
cussedandrecordedintheirnotesthanthosereceiving
no active intervention for a previously declared drug
problem, which might introduce differential bias and
explaintheapparenteffectsofopiatesubstitutiontreat-
ment on long term cessation. We found the same rela-
tion between opiate substitution treatment exposure
and long term cessation shown in figure 2, however,
when we restricted the analysis to survivors with inter-
view data.
Continued injecting among those who received opi-
ate substitution treatment might reflect poor prescrib-
ingorinadequatedosesofthesubstitutedruginvolved,
both of which were associated with a higher risk of
mortality in other studies in Scotland.
38 This seems
unlikely. Doses prescribed at Muirhouse are typically
high(currentmeandailydoseofmethadoneis90 mg).
Someopiatesubstitutiontreatment,particularlybefore
the 1990s, could have been at lower doses.
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Fig 2 | Survival: probability of not dying before long term
cessation by exposure to opiate substitution to treatment
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page 6 of 8 BMJ | ONLINE FIRST | bmj.comNevertheless,thiswouldnotexplainwhythosewithno
exposure to opiate substitution treatment have a
shorter duration of injecting; and the substantial survi-
val benefits seen with opiate substitution treatment,
particularly when prescribed for longer periods, also
seems inconsistent if opiate substitution treatment
was prescribed at an inadequate dose.
Conclusions
Injecting opiate use is typically a chronic health pro-
blem with substantial adverse health consequences.
These consequences are ameliorated in part by oral
opiate substitution treatment, the beneficial effects of
which seem to be more substantial the longer it is pre-
scribed. These benefits, however, do not seem to be
mediated through reductions in the overall duration
of injecting and might be associated with prolonged
duration, albeit at reduced frequency during treat-
ment. The implication is that prescribing guidelines
that emphasise the key importance of complete cessa-
tion of injection or suggest that opiate substitution
treatment should be withheld from injecting drug
users with evidence of continued injecting are inap-
propriate and indeed likely to increase mortality.
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